# Efficacy and Safety of SR1375 in Adult Patients With CAP

> **NCT06577558** · PHASE2 · RECRUITING · sponsor: **Shanghai SIMR Biotechnology Co., Ltd.** · enrollment: 240 (estimated)

## Conditions studied

- Community-acquired Pneumonia

## Interventions

- **DRUG:** SR1375 capsule 3mg+regular treatments
- **DRUG:** SR1375 capsule 1mg+regular treatments
- **DRUG:** SR1375 capsule 0.3mg+regular treatments
- **DRUG:** Placebo capsule+regular treatments

## Key facts

- **NCT ID:** NCT06577558
- **Lead sponsor:** Shanghai SIMR Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-10
- **Primary completion:** 2025-10-15
- **Final completion:** 2025-10-30
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2025-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06577558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06577558, "Efficacy and Safety of SR1375 in Adult Patients With CAP". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT06577558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*